Dr. Sharsti Sandall, PhDExecutive Director, ADC Biology at PfizerSpeaker
Profile
Sharsti Sandall is the Executive Director, Head of ADC Biology, for the Oncology ADC Discovery Research group. In this role, she leads a 60+ member team that is responsible for driving the ADC biology research for the Pfizer ADC discovery and clinical portfolio. Prior to joining Pfizer, she spent 10+ years at Seagen initiating and leading the research efforts for several ADCs, leading to multiple development candidates. She is particularly focused on expanding our understanding of the parameters for pairing the right target, linker, and payload as well as broadening the understanding of ADC sensitivity and resistance. Prior to joining Seagen, Sharsti was a Damon Runyon Postdoctoral Fellow at the Salk Institute for Biological Studies studying the adult tissue stem cell niche. She earned her BS in Microbiology from CSU, Long Beach and her PhD in Biomedical Sciences from the University of California, San Diego where she uncovered novel insights into mitotic spindle function.
Agenda Sessions
Insights from a Decade of Clinical Experience with Vedotin ADCs: Target Selection, Tumor Type, and Combination Strategies
, 11:30amView Session